Talk:Adrenocorticotropic hormone (medication)
![]() | Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Adrenocorticotropic hormone (medication).
|
This is the talk page for discussing improvements to the Adrenocorticotropic hormone (medication) article. This is not a forum for general discussion of the article's subject. |
Article policies
|
Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL |
![]() | This article is rated B-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | ||||||||||||||||||||
|
![]() | The contents of Tetracosactide was merged into Adrenocorticotropic hormone (medication). The former page's history now serves to provide attribution for that content in the latter page, and it must not be deleted as long as the latter page exists. For the discussion at that location, see its talk page. |
JAMA Internal Medicine 2017
[edit]This article discusses the high cost and lack of evidence for many indications.
http://jamanetwork.com/journals/jamainternalmedicine/article-abstract/2653010 Trends and Characteristics of US Medicare Spending on Repository Corticotropin Daniel M. Hartung, PharmD, MPH; Kirbee Johnston, MPH; Shelby Van Leuven; et al. JAMA Intern Med. September 11, 2017. doi:10.1001/jamainternmed.2017.3631
This study uses Medicare Drug Spending Dashboard data to estimate the cost of repository corticotropin to the Medicare program and assess its within-specialty prescribing patterns.
Repository corticotropin (rACTH) injection (H. P. Acthar gel; Mallinckrodt Pharmaceuticals) has been under intense scrutiny for its very high cost.1,2 Because rACTH is approved for a variety of immunologic conditions prevalent in the US Medicare population, prescriptions for rACTH may have a significant financial impact on Medicare expenditures. The objectives of this study were to (1) estimate the cost of rACTH to the Medicare program, and (2) assess the within-specialty prescribing patterns for this medication.
--Nbauman (talk) 04:30, 12 September 2017 (UTC)
Move discussion in progress
[edit]There is a move discussion in progress on Talk:Lithium (medication) which affects this page. Please participate on that page and not in this talk page section. Thank you. —RMCD bot 23:15, 28 January 2019 (UTC)